These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2569203)

  • 41. The quantitative measurement of changes in EEG frequency spectra produced in the cat by sedative-hypnotics and neuroleptics.
    Fairchild MD; Jenden DJ; Mickey MR; Yale C
    Electroencephalogr Clin Neurophysiol; 1980 Aug; 49(3-4):382-90. PubMed ID: 6158416
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Potentiation of the psychotropic effect of chlorpromazine by metoclopramide.
    Hemnani TJ; Dashputra PG
    Indian J Med Res; 1983 Oct; 78():593-5. PubMed ID: 6668017
    [No Abstract]   [Full Text] [Related]  

  • 43. Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice.
    Broekkamp CL; Rijk HW; Joly-Gelouin D; Lloyd KL
    Eur J Pharmacol; 1986 Jul; 126(3):223-9. PubMed ID: 2875886
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of cyanide in the production of the central depressant effects of gamma-phthalimido-butyro-nitrile.
    Askew BM; Cambridge GW
    Arch Int Pharmacodyn Ther; 1965 Nov; 158(1):173-86. PubMed ID: 5854044
    [No Abstract]   [Full Text] [Related]  

  • 45. Inhibition of conditioned avoidance response by a new neuroleptic (LR 511). Interference with drugs endowed with different CNS activity.
    Chieli T; Fregnan GB
    Pharmacol Res Commun; 1979 Jul; 11(7):617-22. PubMed ID: 41268
    [No Abstract]   [Full Text] [Related]  

  • 46. Isolation-induced social behavioral deficit test: effect of tranquilizing drugs.
    Frances H; Lienard C
    Pharmacol Biochem Behav; 1989 Oct; 34(2):293-6. PubMed ID: 2576135
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neuroleptic and anti-depressant drug treatment abolishes conditioned immunosuppression in mice.
    Gorczynski RM; Holmes W
    Brain Behav Immun; 1989 Dec; 3(4):312-9. PubMed ID: 2575410
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Glial reactivity after antipsychotic treatment. An experimental study in rats and its implications for psychiatry.
    Blázquez Arroyo JL; Fraile Malmierca E; Casadiego Cubides A; Llorca Ramón G; Ledesma Jimeno A
    Actas Esp Psiquiatr; 2010; 38(5):278-84. PubMed ID: 21117002
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of psychotropic drugs on methamphetamine-induced behavioral excitation in grouped mice.
    Shintomi K
    Eur J Pharmacol; 1975 Apr; 31(2):195-206. PubMed ID: 238852
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ["A drug potent enough to cause artificial hibernation". Discovery of chlorpromazine changed psychiatry].
    Ajanki T
    Lakartidningen; 2005 Jan 17-23; 102(3):144-5. PubMed ID: 15712740
    [No Abstract]   [Full Text] [Related]  

  • 51. Correlation between distal nephron enzyme activity, structure and function in rats during lithium and lithium plus neuroleptic treatment.
    Nørgaard T; Faarup P; Hansen BB; Kristensen AR; Christensen S
    Ren Physiol; 1985; 8(1):50-61. PubMed ID: 2857495
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ethopharmacology of social conflict and communication: anxiolytics, antidepressants, antipsychotics, and analgesics. Second international meeting of the European Behavioural Pharmacology Society. Athens, Greece, 31 August-3 September 1988. Proceedings.
    Psychopharmacology (Berl); 1989; 97(2):141-283. PubMed ID: 2567020
    [No Abstract]   [Full Text] [Related]  

  • 53. The effects of antianxiety and antipsychotic drugs and sexual behavior.
    Shader RI; Elkins R
    Mod Probl Pharmacopsychiatry; 1980; 15():91-110. PubMed ID: 6106892
    [No Abstract]   [Full Text] [Related]  

  • 54. Effects of lithium and neuroleptics and combinations of the two on renal function and structure in rats.
    Christensen S; Kristensen AR; Faarup P
    Acta Pharmacol Toxicol (Copenh); 1981 Sep; 49(3):161-7. PubMed ID: 6121456
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis and preliminary behavioural evaluation in mice of new 3-aryl-3-pyrrol-1-ylpropanamides, analogues of FGIN-1-27 and FGIN-1-43.
    Guillon J; Boulouard M; Lelong V; Dallemagne P; Rault S; Jarry C
    J Pharm Pharmacol; 2001 Nov; 53(11):1561-8. PubMed ID: 11732760
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased sensitivity to neuroleptics in rats with lesions of the central nervous system.
    Delini-Stula A
    Psychopharmacologia; 1972; 26(1):84-90. PubMed ID: 5065892
    [No Abstract]   [Full Text] [Related]  

  • 57. The effect of chlorpromazine and haloperidol on DNA transcription.
    Barak Y; Ron IG; Sirota P; Sobe T; Slor H
    Int Clin Psychopharmacol; 1996 Sep; 11(3):193-7. PubMed ID: 8923098
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evidence for drug actions on both pre- and postsynaptic catecholamine receptors in the CNS.
    Bunney BS; Aghajanian GK
    Psychopharmacol Bull; 1975 Oct; 11(4):8-10. PubMed ID: 724
    [No Abstract]   [Full Text] [Related]  

  • 59. Potentiation in rats of bufotenin-induced behavioral changes by chlorpromazine.
    Angel C; Burkett ML
    Percept Mot Skills; 1971 Jun; 32(3):803-10. PubMed ID: 5104949
    [No Abstract]   [Full Text] [Related]  

  • 60. A functional genomic study of the effects of antipsychotic agent chlorpromazine in PC12 cells.
    Kontkanen O; Lakso M; Wong G; Castrén E
    Clin Chem Lab Med; 2000 Sep; 38(9):911-5. PubMed ID: 11097349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.